Company Overview and News

7
Money laundering - Wikipedia

2018-06-16 en.wikipedia.org
Money laundering is the act of concealing the transformation of profits from illegal activities and corruption into ostensibly "legitimate" assets.[1] The dilemma of illicit activities is accounting for the origin of the proceeds of such activities without raising the suspicion of law enforcement agencies. Accordingly, considerable time and effort is put into devising strategies which enable the safe use of those proceeds without raising unwanted suspicion.
BNPZY WU BNPQY BNPQF

6
The Fed has taken the first step toward an early exit from its balance sheet reduction

2018-06-14 cnbc
The Federal Reserve has been selling bonds it purchased to pull the economy out of the financial crisis. Now, it has begun preparing for what could be an early end to this program.
BNPZY BNPQY BNPQF

6
UPDATE 1-France's Teleperformance agrees $1 bln deal to buy Intelenet from Blackstone

2018-06-14 reuters
(Reuters) - Teleperformance (ROCH.PA) has agreed to buy India-based Intelenet from U.S. private equity firm Blackstone (BX.N) in a $1 billion deal aimed at strengthening its specialized services business, the French company said.
BNPZY BNPQY BNPQF

6
BNP Paribas Announces Senior Staff Appointments in the USA and the Americas

2018-06-14 globenewswire
NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- As BNP Paribas continues to evolve its platform in the region and build on the significant growth to date, as well as reinforce its commitment to clients, it is pleased to announce the appointments of several executive members:
BNPZY FHB BNPQY BNPQF

6
Wall Street sees two more Fed hikes in 2018, three in 2019

2018-06-13 theedgemarkets
(June 14): Wall Street's top banks expect the U.S. Federal Reserve to raise interest rates twice more this year and three times in 2019, in line with forecasts issued Wednesday by central bank policy makers who signaled a modest acceleration to their pace of rate hikes along with increased confidence in the economy.
BNPZY BNPQY BNPQF

10
RBI may hike rates again in August on rise in inflation: Analysts

2018-06-13 moneycontrol
Headline inflation surging to a four-month high of 4.87 per cent in May is likely to force the Reserve Bank of India (RBI) to hike rates once again at its August monetary policy review, analysts said.
BNPZY DB BNPQY BNPQF

22
Investments Pour out of EM Funds, but Why? | Chief Investment Officer

2018-06-13 ai-cio
The end of the emerging market boom doesn’t mean that these stocks are in a death spiral.
BNPZY MS.PRI MS.PRK BNPQY MS.PRE MS.PRF MS.PRG BNPQF MS MS.PRA MSCI

6
BNP Paribas Appoints Sonja Volpe as New President and CEO for Canada

2018-06-12 globenewswire
MONTREAL, June 12, 2018 (GLOBE NEWSWIRE) -- BNP Paribas is pleased to announce that effective July 1, 2018 it has appointed Mrs Sonja Volpe as its new President and Chief Executive Officer for Canada.
BNPZY BNPQY BNPQF

6
Outokumpu will issue EUR 250 million bond

2018-06-11 globenewswire
Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan or Singapore, or any other jurisdiction in which the distribution or release would be unlawful.
BNPZY SWDBY SWDBF NRDEF BNPQY DNSKY BNPQF DNKEY DNSKF NRBAY

6
Outokumpu laskee liikkeeseen 250 miljoonan euron joukkovelkakirjalainan

2018-06-11 globenewswire
Outokumpu laskee liikkeeseen 250 miljoonan euron joukkovelkakirjalainan Ei julkistettavaksi tai levitettäväksi, suoraan tai välillisesti, Yhdysvalloissa, Australiassa, Kanadassa, Hongkongissa, Japanissa tai Singaporessa tai missään muussa valtiossa, jossa levittäminen tai julkistaminen olisi lainvastaista.
BNPZY SWDBY SWDBF NRDEF BNPQY DNSKY BNPQF DNKEY DNSKF NRBAY

12
EU mergers and takeovers (June 8)

2018-06-08 reuters
BRUSSELS, June 8 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF DTEGF SMFNF ICP BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

6
Luxury sales are rebounding in China. Just not in stores

2018-06-08 sfgate
After several years of slumber, China’s luxury market is finally returning to growth. You would not know that, though, from peering into its — mostly empty — high-end stores.
BNPZY BNPQY BNPQF

12
EU mergers and takeovers (June 7)

2018-06-07 reuters
BRUSSELS, June 7 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF SMFNF DTEGF BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

9
Top French banks appoint graduate school contemporaries of Macron - Channel NewsAsia

2018-06-07 channelnewsasia
France's biggest banks BNP Paribas and Societe Generale have appointed to senior posts former graduate school contemporaries of President Emmanuel Macron, suggesting the institutions want to keep close ties with the political establishment.
BNPZY SCGLF BNPQY SCGLY GLE BNPQF

6
BNP Paribas forecasts euro rebound to $1.23, ECB to raise rates twice in 2019

2018-06-07 reuters
LONDON (Reuters) - French lender BNP Paribas (BNPP.PA) said on Thursday it expects the euro to rise more than 4 percent to $1.23 EUR= in three months from current levels as the market is underpricing the chances of the European Central Bank tightening monetary policy.
BNPZY BNPQY BNPQF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 007309681